2009-12-08-世界卫生组织-INN_Proposed_List_102_50页_453kb

WHO Drug Information Vol. 23, No. 4, 2009 presents a list of proposed International Nonproprietary Names (INN) for pharmaceutical substances, specifically List 102. These names are provisional and not yet recommended or included in the Cumulative Lists of INNs. The inclusion does not imply endorsement for any specific medical use. Comments and formal objections can be submitted within four months of publication (by 31 May 2010 for List 102) to the INN Programme of WHO.

The document includes a detailed list of proposed INN names for various substances, covering a wide range of therapeutic classes, such as antibiotics, antineoplastics, immunomodulators, and others. Each entry typically provides the common name, chemical name, action or use, molecular formula, CAS registry number, and graphic formula. For example, acidum zibrofusidicum is a proposed antibiotic with a specific chemical structure, while afatinibum is a kinase inhibitor used in cancer treatment.

Amendments to previous INN lists are noted, such as a change in the name for a compound from inolitazonum to efatutazonum in List 99.

The procedure for selecting recommended INNs outlines that proposals must be submitted to WHO with a fee; the INN Expert Group reviews them. Comments can be made from any person, and formal objections may lead to name reconsideration or substitution. No name can be selected if a formal objection is pending withdrawal. Substitution can be proposed in extraordinary circumstances, such as to prevent medication errors.

General principles for devising INNs emphasize that names should be distinctive, not confusing, and may reflect pharmacological relationships. Secondary principles include avoiding isolated letters or hyphens, using substituted letters (e.g., 'f' for 'ph'), and prioritizing names suggested by discoverers or those in common use.

The document includes annexes with the same information in French, Spanish, and Portuguese for international use.

This list represents 102 new proposed nonproprietary names for pharmaceutical substances pending WHO review and potential recommendation.